Expert Interviews

Ruta Rao, MD, discusses her rationale for treating metastatic HER2+ breast cancer with a tucatinib-containing regimen based on data from the HER2CLIMB trial.

Stefania Maraka, MD, explains the second- and third-line treatment options for metastatic HER2+ breast cancer and how she collaborates with breast oncologists.

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about how enrollment for specific trials in renal cell carcinoma may incorporate a patient’s tumor histology.

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, spoke about ongoing trials may hold promise for the treatment of patients with bladder cancer.

In an interview with CancerNetwork®, Ursula A. Matulonis, MD, discusses the toxicities associated with mirvetuximab soravtansine in folate receptor α–high platinum-resistant ovarian cancer.

Frederick Lock, MD, spoke about how future research regarding axicabtagene ciloleucel for patients with large B-cell lymphoma will progress.

A look at the unmet needs and future directions of multiple myeloma treatment.

Oncologists highlight novel agents currently being investigated for the treatment of relapsed/refractory multiple myeloma.

Thomas Powles, MBBS, MRCP, MD, discusses recent data from the JAVELIN Bladder 100 trial on maintenance avelumab therapy plus best supportive care versus BSC alone.

Experts discuss the role of biomarkers in treatment selection for patients with metastatic UC.

A look at the current unmet needs in front-line renal cell carcinoma treatment.

Oncologists review quality of life data for patients with renal cell carcinoma receiving lenvatinib plus pembrolizumab combination treatments.

Yi-Bin Chen, MD, reviews factors affecting treatment selection among available pharmacological and ex vivo prophylaxis approaches for GVHD.

Thought leaders in stem cell transplant and cellular immunotherapy share insights into how they counsel patients about the challenges associated with the long-term management of chronic GVHD.

Susan F. Slovin, MD, PhD, spoke about how new approaches can support clinical practice guidelines and physician intuition in treating patients with prostate cancer.

At SGO 2022, Catherine Watson, MD, spoke about how to improve genetic education for patients with ovarian cancer.

Chung-Han Lee, MD, PhD, discusses data from the JAVELIN Renal 101 trial of axitinib/avelumab versus sunitinib in metastatic RCC.

Mehmet Asim Bilen, MD, summarizes data from the CheckMate 214 trial on the safety and efficacy of ipilimumab/nivolumab versus sunitinib.

Lori Wirth, MD, discusses the unmet needs and ongoing trials in development for patients with RR-DTC.

Switching to a patient scenario of metastatic hormone-sensitive prostate cancer, experts discuss which therapeutic approach they would undertake.

A brief discussion on the role of PSMA-targeted therapy’s role in managing patients with nonmetastatic castration-resistant prostate cancer.

Scott T. Tagawa, MD, spoke about potential approvals in the coming year for prostate cancer.

Kidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.

An explanation of dosing strategies when treating patients with renal cell carcinoma in the first-line with lenvatinib.

Experts discuss the safety of treating renal cell carcinoma with lenvatinib within different patient risk populations.

Possible comorbidities and other risk factors in advanced renal cell carcinoma that would affect potential treatment regimens.

Lori Wirth, MD, discusses the role of cabozantinib in the second-line setting for patients with radioiodine-refractory differentiated thyroid cancer and reviews the results from the COSMIC-311 trial.

Key takeaways from the CARTITUDE-1 study and the KarMMA study evaluating CAR T-cell therapies for relapsed/refractory multiple myeloma.

An overview of BCMA-targeting bispecific agents in development for multiple myeloma, including talquetamab and teclistamab.

A panel of doctors discuss the available treatment options for early and late relapsed multiple myeloma, including approved novel BCMA-targeting agents.